[{"orgOrder":0,"company":"Servier","sponsor":"Servier","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"PEPIDH1M Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Servier \/ Servier","highestDevelopmentStatusID":"6","companyTruncated":"Servier \/ Servier"},{"orgOrder":0,"company":"Servier","sponsor":"Servier","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Futuximab","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase III","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Servier \/ Servier","highestDevelopmentStatusID":"10","companyTruncated":"Servier \/ Servier"},{"orgOrder":0,"company":"Servier","sponsor":"Servier","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Peg L asparaginase","moa":"Asparagine","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Servier \/ Servier","highestDevelopmentStatusID":"9","companyTruncated":"Servier \/ Servier"},{"orgOrder":0,"company":"Servier","sponsor":"Servier","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"S95014","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Servier \/ Servier","highestDevelopmentStatusID":"8","companyTruncated":"Servier \/ Servier"},{"orgOrder":0,"company":"Servier","sponsor":"Servier","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"S95014","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Servier \/ Servier","highestDevelopmentStatusID":"8","companyTruncated":"Servier \/ Servier"},{"orgOrder":0,"company":"Servier","sponsor":"Precision BioSciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"Azercabtagene Zapreleucel","moa":"||CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Servier","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Servier \/ Precision BioSciences","highestDevelopmentStatusID":"7","companyTruncated":"Servier \/ Precision BioSciences"},{"orgOrder":0,"company":"Servier","sponsor":"Merck & Co | Servier","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"S095029","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Servier \/ Merck & Co | Servier","highestDevelopmentStatusID":"7","companyTruncated":"Servier \/ Merck & Co | Servier"},{"orgOrder":0,"company":"Servier","sponsor":"Servier | Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"S095018","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Servier \/ Servier | Regeneron Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Servier \/ Servier | Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Servier","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"S227928","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Servier \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Servier \/ Inapplicable"},{"orgOrder":0,"company":"Servier","sponsor":"Servier","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"S095029","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Servier \/ Servier","highestDevelopmentStatusID":"6","companyTruncated":"Servier \/ Servier"},{"orgOrder":0,"company":"Servier","sponsor":"Oncodesign Services","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Servier \/ Servier","highestDevelopmentStatusID":"2","companyTruncated":"Servier \/ Servier"},{"orgOrder":0,"company":"Servier","sponsor":"Aitia","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Servier \/ Aitia","highestDevelopmentStatusID":"2","companyTruncated":"Servier \/ Aitia"},{"orgOrder":0,"company":"Servier","sponsor":"Taiho Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Trifluridine","moa":"||DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Servier \/ Servier","highestDevelopmentStatusID":"15","companyTruncated":"Servier \/ Servier"},{"orgOrder":0,"company":"Servier","sponsor":"Mission Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ivosidenib","moa":"||Isocitrate dehydrogenase [NADP] cytoplasmic","graph1":"Oncology","graph2":"Approved FDF","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Servier \/ Mission Bio","highestDevelopmentStatusID":"15","companyTruncated":"Servier \/ Mission Bio"},{"orgOrder":0,"company":"Servier","sponsor":"Agios Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Ivosidenib","moa":"Isocitrate dehydrogenase [NADP] cytoplasmic","graph1":"Oncology","graph2":"Approved FDF","graph3":"Servier","amount2":2,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":2,"dosageForm":"Tablet","sponsorNew":"Servier \/ Servier","highestDevelopmentStatusID":"15","companyTruncated":"Servier \/ Servier"},{"orgOrder":0,"company":"Servier","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ivosidenib","moa":"Isocitrate dehydrogenase [NADP] cytoplasmic","graph1":"Oncology","graph2":"Approved FDF","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Servier \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Servier \/ Inapplicable"},{"orgOrder":0,"company":"Servier","sponsor":"Taiho Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Trifluridine","moa":"||DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Servier \/ Taiho Oncology","highestDevelopmentStatusID":"15","companyTruncated":"Servier \/ Taiho Oncology"},{"orgOrder":0,"company":"Servier","sponsor":"Onco360","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ivosidenib","moa":"Isocitrate dehydrogenase [NADP] cytoplasmic","graph1":"Oncology","graph2":"Approved FDF","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Servier \/ Servier","highestDevelopmentStatusID":"15","companyTruncated":"Servier \/ Servier"},{"orgOrder":0,"company":"Servier","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ivosidenib","moa":"Isocitrate dehydrogenase [NADP] cytoplasmic","graph1":"Oncology","graph2":"Approved FDF","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Servier \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Servier \/ Inapplicable"},{"orgOrder":0,"company":"Servier","sponsor":"Idorsia Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ivosidenib","moa":"Isocitrate dehydrogenase [NADP] cytoplasmic","graph1":"Oncology","graph2":"Approved FDF","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Servier \/ Idorsia Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Servier \/ Idorsia Pharmaceuticals"},{"orgOrder":0,"company":"Servier","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vorasidenib","moa":"IDH1\/IDH2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Servier \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Servier \/ Inapplicable"},{"orgOrder":0,"company":"Servier","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ivosidenib","moa":"Isocitrate dehydrogenase [NADP] cytoplasmic","graph1":"Oncology","graph2":"Approved FDF","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Servier \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Servier \/ Inapplicable"},{"orgOrder":0,"company":"Servier","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ivosidenib","moa":"||Isocitrate dehydrogenase [NADP] cytoplasmic","graph1":"Oncology","graph2":"Approved FDF","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Servier \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Servier \/ Inapplicable"},{"orgOrder":0,"company":"Servier","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ivosidenib","moa":"||Isocitrate dehydrogenase [NADP] cytoplasmic","graph1":"Oncology","graph2":"Approved FDF","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Servier \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Servier \/ Inapplicable"},{"orgOrder":0,"company":"Servier","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ivosidenib","moa":"||Isocitrate dehydrogenase [NADP] cytoplasmic","graph1":"Oncology","graph2":"Approved FDF","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Servier \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Servier \/ Inapplicable"},{"orgOrder":0,"company":"Servier","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ivosidenib","moa":"||Isocitrate dehydrogenase [NADP] cytoplasmic","graph1":"Oncology","graph2":"Approved FDF","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Servier \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Servier \/ Inapplicable"},{"orgOrder":0,"company":"Servier","sponsor":"Servier","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ivosidenib","moa":"Isocitrate dehydrogenase [NADP] cytoplasmic","graph1":"Oncology","graph2":"Phase III","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Servier \/ Servier","highestDevelopmentStatusID":"10","companyTruncated":"Servier \/ Servier"},{"orgOrder":0,"company":"Servier","sponsor":"Servier","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ivosidenib","moa":"Isocitrate dehydrogenase [NADP] cytoplasmic","graph1":"Oncology","graph2":"Approved FDF","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Servier \/ Servier","highestDevelopmentStatusID":"15","companyTruncated":"Servier \/ Servier"},{"orgOrder":0,"company":"Servier","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Vorasidenib","moa":"IDH1\/IDH2","graph1":"Oncology","graph2":"Phase III","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Servier \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Servier \/ Inapplicable"},{"orgOrder":0,"company":"Servier","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Ivosidenib","moa":"Isocitrate dehydrogenase [NADP] cytoplasmic","graph1":"Oncology","graph2":"Phase III","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Servier \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Servier \/ Inapplicable"},{"orgOrder":0,"company":"Servier","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ivosidenib","moa":"Isocitrate dehydrogenase [NADP] cytoplasmic","graph1":"Oncology","graph2":"Approved FDF","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Servier \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Servier \/ Inapplicable"},{"orgOrder":0,"company":"Servier","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vorasidenib","moa":"IDH1\/IDH2","graph1":"Oncology","graph2":"Phase III","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Servier \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Servier \/ Inapplicable"},{"orgOrder":0,"company":"Servier","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vorasidenib","moa":"IDH1\/IDH2","graph1":"Oncology","graph2":"Phase III","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Servier \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Servier \/ Inapplicable"},{"orgOrder":0,"company":"Servier","sponsor":"Agios Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Vorasidenib","moa":"IDH1\/IDH2","graph1":"Oncology","graph2":"Phase III","graph3":"Servier","amount2":2,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":2,"dosageForm":"Tablet, Film Coated","sponsorNew":"Servier \/ Servier","highestDevelopmentStatusID":"10","companyTruncated":"Servier \/ Servier"},{"orgOrder":0,"company":"Servier","sponsor":"Taiho Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Trifluridine","moa":"||DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Servier \/ Taiho Oncology","highestDevelopmentStatusID":"15","companyTruncated":"Servier \/ Taiho Oncology"},{"orgOrder":0,"company":"Servier","sponsor":"Servier","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Atorvastatin","moa":"HMG-CoA reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Servier \/ Servier","highestDevelopmentStatusID":"10","companyTruncated":"Servier \/ Servier"},{"orgOrder":0,"company":"Servier","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Amlodipine","moa":"Voltage-gated L-type calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Servier \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Servier \/ Inapplicable"},{"orgOrder":0,"company":"Servier","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ivosidenib","moa":"Isocitrate dehydrogenase [NADP] cytoplasmic","graph1":"Oncology","graph2":"Approved FDF","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Servier \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Servier \/ Inapplicable"},{"orgOrder":0,"company":"Servier","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vorasidenib","moa":"IDH1\/IDH2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Servier \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Servier \/ Inapplicable"},{"orgOrder":0,"company":"Servier","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vorasidenib","moa":"IDH1\/IDH2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Servier \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Servier \/ Inapplicable"},{"orgOrder":0,"company":"Servier","sponsor":"Servier","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Micronized Purified Flavonoid- Fraction","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Servier \/ Servier","highestDevelopmentStatusID":"10","companyTruncated":"Servier \/ Servier"},{"orgOrder":0,"company":"Servier","sponsor":"Servier","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Trifluridine","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Servier \/ Servier","highestDevelopmentStatusID":"8","companyTruncated":"Servier \/ Servier"},{"orgOrder":0,"company":"Servier","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ivosidenib","moa":"Isocitrate dehydrogenase [NADP] cytoplasmic","graph1":"Oncology","graph2":"Approved FDF","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Servier \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Servier \/ Inapplicable"},{"orgOrder":0,"company":"Servier","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ivosidenib","moa":"Isocitrate dehydrogenase [NADP] cytoplasmic","graph1":"Oncology","graph2":"Phase II","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Servier \/ Servier","highestDevelopmentStatusID":"8","companyTruncated":"Servier \/ Servier"},{"orgOrder":0,"company":"Servier","sponsor":"Servier","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"S095035","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Servier \/ Servier","highestDevelopmentStatusID":"7","companyTruncated":"Servier \/ Servier"},{"orgOrder":0,"company":"Servier","sponsor":"Moffitt Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Hyper Cvad Protocol","moa":"Multiple","graph1":"Oncology","graph2":"Phase I","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Servier \/ Servier","highestDevelopmentStatusID":"6","companyTruncated":"Servier \/ Servier"},{"orgOrder":0,"company":"Servier","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vorasidenib","moa":"IDH1\/IDH2","graph1":"Oncology","graph2":"Phase I","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Servier \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Servier \/ Merck & Co"},{"orgOrder":0,"company":"Servier","sponsor":"Servier","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vorasidenib","moa":"IDH1\/IDH2","graph1":"Undisclosed","graph2":"Phase I","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Servier \/ Servier","highestDevelopmentStatusID":"6","companyTruncated":"Servier \/ Servier"},{"orgOrder":0,"company":"Servier","sponsor":"Black Diamond Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"BDTX-4933","moa":"RAS\/RAF","graph1":"Oncology","graph2":"Phase I","graph3":"Servier","amount2":0.78000000000000003,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.78000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Servier \/ Servier","highestDevelopmentStatusID":"6","companyTruncated":"Servier \/ Servier"},{"orgOrder":0,"company":"Servier","sponsor":"Mina Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Servier","amount2":0.26000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0.26000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Servier \/ Servier","highestDevelopmentStatusID":"3","companyTruncated":"Servier \/ Servier"},{"orgOrder":0,"company":"Servier","sponsor":"Base4 Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Servier \/ Servier","highestDevelopmentStatusID":"3","companyTruncated":"Servier \/ Servier"},{"orgOrder":0,"company":"Servier","sponsor":"Aqemia","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Servier \/ Servier","highestDevelopmentStatusID":"4","companyTruncated":"Servier \/ Servier"},{"orgOrder":0,"company":"Servier","sponsor":"Celsius Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Servier","amount2":0.69999999999999996,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.69999999999999996,"dosageForm":"Undisclosed","sponsorNew":"Servier \/ Servier","highestDevelopmentStatusID":"2","companyTruncated":"Servier \/ Servier"},{"orgOrder":0,"company":"Servier","sponsor":"Servier","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vorasidenib","moa":"IDH1\/IDH2","graph1":"Oncology","graph2":"Phase III","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Servier \/ Servier","highestDevelopmentStatusID":"10","companyTruncated":"Servier \/ Servier"},{"orgOrder":0,"company":"Servier","sponsor":"Servier","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"S 64315","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Servier \/ Servier","highestDevelopmentStatusID":"7","companyTruncated":"Servier \/ Servier"},{"orgOrder":0,"company":"Servier","sponsor":"Servier","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"S65487","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Servier \/ Servier","highestDevelopmentStatusID":"7","companyTruncated":"Servier \/ Servier"},{"orgOrder":0,"company":"Servier","sponsor":"Servier","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase I","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Servier \/ Servier","highestDevelopmentStatusID":"6","companyTruncated":"Servier \/ Servier"},{"orgOrder":0,"company":"Servier","sponsor":"Servier","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Perindopril","moa":"Angiotensin-converting enzyme","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Servier \/ Servier","highestDevelopmentStatusID":"11","companyTruncated":"Servier \/ Servier"},{"orgOrder":0,"company":"Servier","sponsor":"Taiho Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Trifluridine","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Servier \/ Servier","highestDevelopmentStatusID":"15","companyTruncated":"Servier \/ Servier"},{"orgOrder":0,"company":"Servier","sponsor":"OSE Immunotherapeutics SA","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Lusvertikimab","moa":"monoclonal antibodies: interleukins","graph1":"Immunology","graph2":"Phase II","graph3":"Servier","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Servier \/ Servier","highestDevelopmentStatusID":"8","companyTruncated":"Servier \/ Servier"},{"orgOrder":0,"company":"Servier","sponsor":"Servier","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Trifluridine","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Servier \/ Servier","highestDevelopmentStatusID":"8","companyTruncated":"Servier \/ Servier"},{"orgOrder":0,"company":"Servier","sponsor":"Servier","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Trifluridine","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Servier \/ Servier","highestDevelopmentStatusID":"8","companyTruncated":"Servier \/ Servier"},{"orgOrder":0,"company":"Servier","sponsor":"Servier","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Servier \/ Servier","highestDevelopmentStatusID":"8","companyTruncated":"Servier \/ Servier"},{"orgOrder":0,"company":"Servier","sponsor":"Servier","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"S95011","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Servier \/ Servier","highestDevelopmentStatusID":"8","companyTruncated":"Servier \/ Servier"},{"orgOrder":0,"company":"Servier","sponsor":"Servier","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ivosidenib","moa":"Isocitrate dehydrogenase [NADP] cytoplasmic","graph1":"Oncology","graph2":"Approved FDF","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Servier \/ Servier","highestDevelopmentStatusID":"15","companyTruncated":"Servier \/ Servier"},{"orgOrder":0,"company":"Servier","sponsor":"Servier","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"PRS-344","moa":"PD-L1\/4-1BB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Servier \/ Servier","highestDevelopmentStatusID":"7","companyTruncated":"Servier \/ Servier"},{"orgOrder":0,"company":"Servier","sponsor":"Servier","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"S095033","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Servier \/ Servier","highestDevelopmentStatusID":"7","companyTruncated":"Servier \/ Servier"},{"orgOrder":0,"company":"Symphogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Sym021","moa":"Programmed cell death protein 1 (PD-1)","graph1":"Oncology","graph2":"Phase I","graph3":"Symphogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Symphogen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Symphogen \/ Inapplicable"},{"orgOrder":0,"company":"Servier","sponsor":"Symphogen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2020","type":"Acquisition","leadProduct":"Sym021","moa":"Programmed cell death protein 1 (PD-1)","graph1":"Oncology","graph2":"Phase I","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Servier \/ Servier","highestDevelopmentStatusID":"6","companyTruncated":"Servier \/ Servier"},{"orgOrder":0,"company":"Servier Canada","sponsor":"Symphogen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2020","type":"Acquisition","leadProduct":"Sym021","moa":"Programmed cell death protein 1 (PD-1)","graph1":"Oncology","graph2":"Phase I","graph3":"Servier Canada","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Servier Canada \/ Servier Canada","highestDevelopmentStatusID":"6","companyTruncated":"Servier Canada \/ Servier Canada"},{"orgOrder":0,"company":"Servier","sponsor":"Cellectis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"UCART19","moa":"CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Servier","amount2":0.44,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.44,"dosageForm":"Undisclosed","sponsorNew":"Servier \/ Servier","highestDevelopmentStatusID":"6","companyTruncated":"Servier \/ Servier"},{"orgOrder":0,"company":"Servier Canada","sponsor":"Cellectis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"UCART19","moa":"CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Servier Canada","amount2":0.40999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.40999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Servier Canada \/ Servier Canada","highestDevelopmentStatusID":"6","companyTruncated":"Servier Canada \/ Servier Canada"},{"orgOrder":0,"company":"Symphogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Sym024","moa":"PD-1","graph1":"Oncology","graph2":"Phase I","graph3":"Symphogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Symphogen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Symphogen \/ Inapplicable"},{"orgOrder":0,"company":"Servier","sponsor":"Servier","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"S095012","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Servier \/ Servier","highestDevelopmentStatusID":"6","companyTruncated":"Servier \/ Servier"},{"orgOrder":0,"company":"Servier","sponsor":"GNS healthcare","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Servier \/ Servier","highestDevelopmentStatusID":"2","companyTruncated":"Servier \/ Servier"},{"orgOrder":0,"company":"Servier","sponsor":"Precision BioSciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Servier \/ Servier","highestDevelopmentStatusID":"1","companyTruncated":"Servier \/ Servier"},{"orgOrder":0,"company":"Servier","sponsor":"Oncodesign Services","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Servier","amount2":0.35999999999999999,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0.35999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Servier \/ Servier","highestDevelopmentStatusID":"1","companyTruncated":"Servier \/ Servier"},{"orgOrder":0,"company":"Servier","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Ivosidenib","moa":"Isocitrate dehydrogenase [NADP] cytoplasmic","graph1":"Oncology","graph2":"Phase I","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Servier \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Servier \/ Undisclosed"},{"orgOrder":0,"company":"Servier","sponsor":"Servier","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Trifluridine","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Servier \/ Servier","highestDevelopmentStatusID":"8","companyTruncated":"Servier \/ Servier"},{"orgOrder":0,"company":"Servier","sponsor":"Servier","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Servier \/ Servier","highestDevelopmentStatusID":"8","companyTruncated":"Servier \/ Servier"}]
Find Clinical Drug Pipeline Developments & Deals by Servier
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
